Success Metrics

Clinical Success Rate
87.3%

Based on 55 completed trials

Completion Rate
87%(55/63)
Active Trials
20(18%)
Results Posted
38%(21 trials)
Terminated
8(7%)

Phase Distribution

Ph phase_3
7
6%
Ph not_applicable
9
8%
Ph phase_1
31
27%
Ph early_phase_1
9
8%
Ph phase_4
4
4%
Ph phase_2
49
43%

Phase Distribution

40

Early Stage

49

Mid Stage

11

Late Stage

Phase Distribution109 total trials
Early Phase 1First-in-human
9(8.3%)
Phase 1Safety & dosage
31(28.4%)
Phase 2Efficacy & side effects
49(45.0%)
Phase 3Large-scale testing
7(6.4%)
Phase 4Post-market surveillance
4(3.7%)
N/ANon-phased studies
9(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.4%

55 of 72 finished

Non-Completion Rate

23.6%

17 ended early

Currently Active

20

trials recruiting

Total Trials

114

all time

Status Distribution
Active(26)
Completed(55)
Terminated(17)
Other(16)

Detailed Status

Completed55
Recruiting16
unknown16
Withdrawn9
Terminated8
Not yet recruiting6

Development Timeline

Analytics

Development Status

Total Trials
114
Active
20
Success Rate
87.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 19 (8.3%)
Phase 131 (28.4%)
Phase 249 (45.0%)
Phase 37 (6.4%)
Phase 44 (3.7%)
N/A9 (8.3%)

Trials by Status

withdrawn98%
completed5548%
not_yet_recruiting65%
recruiting1614%
terminated87%
active_not_recruiting44%
unknown1614%

Recent Activity

Clinical Trials (114)

Showing 20 of 114 trialsScroll for more
NCT07527338Phase 2

Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use

Not Yet Recruiting
NCT07624279Phase 2

nVNS, CBD, and SoC for Persistent Post-Traumatic Headache

Not Yet Recruiting
NCT06213233Phase 2

MIVetsCan: Cannabidiol (CBD)-Care Trial

Recruiting
NCT05044819Phase 4

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Active Not Recruiting
NCT04749628Phase 4

Cannabidiol for Bilateral Total Knee Arthroplasty

Completed
NCT03518801Phase 2

Cannabidiol and Prolonged Exposure

Completed
NCT07564245Phase 2

Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders.

Not Yet Recruiting
NCT07549256Phase 2

Cannabidiol for Pain Relief of Patients With End-stage mCRPC

Not Yet Recruiting
NCT05457465Phase 2

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Recruiting
NCT03984565Phase 2

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Recruiting
NCT06477406Phase 2

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Recruiting
NCT05942911Phase 2

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

Terminated
NCT05651607Phase 2

Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa

Completed
NCT04550377Phase 2

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

Recruiting
NCT04978428Phase 2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

Completed
NCT06854783Phase 1

Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

Completed
NCT04105231Phase 2

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Active Not Recruiting
NCT05388058Phase 2

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Completed
NCT05571592Phase 2

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Completed
NCT05632627Phase 2

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Completed

Drug Details

Intervention Type
DRUG
Total Trials
114